Group 1 - The core transaction of WuXi AppTec occurred on September 12, with a volume of 57,500 shares and a transaction amount of 6.0645 million yuan, at a price of 105.47 yuan per share [2] - In the last three months, WuXi AppTec has recorded a total of four block trades, amounting to 43.623 million yuan [3] - The closing price of WuXi AppTec on the day of the transaction was 105.47 yuan, reflecting an increase of 0.78%, with a daily turnover rate of 2.29% and a total trading volume of 5.955 billion yuan [3] Group 2 - The latest margin financing balance for WuXi AppTec is 6.072 billion yuan, which has increased by 188 million yuan over the past five days, representing a growth rate of 3.19% [4] - The block trade on September 12 was executed by the proprietary trading department of China Merchants Securities Co., Ltd., with the selling department also being from the same company [2][4]

未平仓空仓比减少最大的10只股票 | 股票名称 | 上一次空仓比 | 最新空仓比 | | 减少值↓ | | --- | --- | --- | --- | --- | | 赣锋锂业(01772) | 12.46% | 10.63% | -1.84% | | | 中兴通讯(00763) | 16.47% | 14.96% | -1.51% | | | 晶泰控股(02228) | 4.00% | 2.64% | -1.36% | | | 康希诺生物(06185) | 3.36% | 2.36% | -1.01% | | | 中国软件国际(00354) | 8.05% | 7.11% | -0.94% | | 前10大未平仓空仓比 | 股票名称 | 前次空仓数 | 本次空仓数 | 最新空仓比↓ | | --- | --- | --- | --- | | 中兴通讯(00763) | 1.24 亿股 | 1.13 亿股 | 14.96% | | 中远海控(01919) | 4.01 亿股 | 4.08 亿股 | 14.17% | | 宁德时代(03750) | 2164.51 万股 | 2115.51 万股 | 13. ...

| 交易日期 | 证券简称 | 蓬券代码 | 成交价(元) 成交金额[万元] 成交量(*) 莫入营业部 | | | 美出营业图 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | | 025-09-12 | 药明康德 | 603259 | 105.47 606.45 | 5.75 | 招商证券股份有限 公司内设置业部( | 招商证券股份有限 公司西安曲江新区 we would country and the can and can a | ga | 9月12日，药明康德大宗交易成交5.75万股，成交额606.45万元，占当日总成交额的0.1%，成交价105.47 元，较市场收盘价105.47元持平。 ...

9月12日，A股三大指数持续震荡，创新药概念午后回升。 相关ETF方面，截至午间收盘，创新药ETF天弘（517380）上午走势呈现"W"型反转，并且午后持续走 强，截至发稿该ETF现涨1.50%，成交额超5800万元。成分股中，诺诚健华-U涨超14%，昭衍新药涨 停，皓元医药、康龙化成、博腾股份等股涨幅居前。 此外，生物医药ETF（159859）涨0.88%，成交额超9000万元。成分股中，君实生物-U、百利天恒、药 明康德等股涨幅居前。 在资金流向方面，截至9月11日收盘，创新药ETF天弘（517380）已连续4日获资金净流入，累计"吸 金"超7900万元；生物医药ETF（159859）也连续3日获资金净流入，"吸金"超2.2亿元。 创新药ETF天弘（517380）是全市场规模最大的横跨沪深港三地的创新药ETF，且是全市场唯一一只跟 踪恒生沪深港创新药精选50指数的ETF产品，该指数实现了A股+港股、创新药+CXO全面覆盖。创新药 ETF天弘（517380）还配置了场外联接基金（A类：014564，C类：014565）。 生物医药ETF（159859）紧密跟踪国证生物医药指数（399441.SZ），该指数布 ...

沪指9月11日上涨1.65%，申万所属行业中，今日上涨的有31个，涨幅居前的行业为通信、电子，涨幅 分别为7.39%、5.96%。医药生物行业今日上涨0.25%。 资金面上看，两市主力资金全天净流入345.18亿元，今日有11个行业主力资金净流入，电子行业主力资 金净流入规模居首，该行业今日上涨5.96%，全天净流入资金217.23亿元，其次是计算机行业，日涨幅 为3.71%，净流入资金为84.79亿元。 主力资金净流出的行业有20个，医药生物行业主力资金净流出规模居首，全天净流出资金39.75亿元， 其次是传媒行业，净流出资金为27.38亿元，净流出资金较多的还有汽车、商贸零售、基础化工等行 业。 医药生物行业今日上涨0.25%，全天主力资金净流出39.75亿元，该行业所属的个股共474只，今日上涨 的有350只，涨停的有2只；下跌的有111只。以资金流向数据进行统计，该行业资金净流入的个股有131 只，其中，净流入资金超5000万元的有8只，净流入资金居首的是济民健康，今日净流入资金2.37亿 元，紧随其后的是舒泰神、热景生物，净流入资金分别为1.55亿元、1.41亿元。医药生物行业资金净流 出个股中，资 ...

9月11日，港股三大指数集体下跌，均止步4连涨行情，市场做多情绪趋于谨慎。 截止收盘，恒生指数跌0.43%险守26000点大关，国企指数、恒生科技指数分别下跌0.73%及0.24%。 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | | 恒生指数 | 7 | 26086.32 | -113.94 | -0.43% | | 800000 | | | | | | 国企指数 | intrieter | 9260.25 | -67.91 | -0.73% | | 800100 | | | | | | 恒生科技指数 | Mala | 5888.77 | -13.92 | -0.24% | | 800700 | . NY | | | | 具体来看： 盘面上，大型科技股普遍走低，尤其是美团跌6%刷新阶段新低；报道称特朗普政府拟限制中国药品，生物医药股集体重挫，创新药概念股跌幅居前；影视 娱乐股、钢铁股、汽车股、内房股、手游股多数低迷。 半导体芯片股涨幅强势；受美联储降息前景支撑，铜、铝等有色金属股表现活跃，军工、苹果概念、建材水泥、重型机械、高铁基建股走强 ...

港股生物医药股集体下挫，中国生物制药、石药集团跌超10%，复星医药跌超7%，药明生物、药明康 德跟跌。 ...

2025.09. 11 本文字数：1261，阅读时长大约2分钟 作者 | 一财阿驴 10:33 沪深两市成交额突破1万亿，较昨日此时放量超300亿。 11:31 A股午盘｜沪指涨1.12% 上证指数涨1.12%，深成指涨2.63%，创业板指涨4.31%。算力硬件、半导体、液冷服务器等板块涨 幅居前，体育、贵金属板块低迷。 | 板块名称 | 张唱 | 涨速 | 涨停数 | | --- | --- | --- | --- | | 元件 | +6.54% | +0.13% | 10 | | 共封装光学(CPO) | +6.13% | +0.18% | 11 | | 中国AI 50 | +4.83% | +0.24% | 3 | | 未曾体 | +4.54% | +0.16% | પ્ય | | PCB概念 | +4.40% | +0.16% | 12 | | 铜缆高速连接 | +4.37% | +0.13% | | | 光刻机 | +4.25% | +0.12% | - | | F5G概念 | +4.22% | +0.20% | | | 国家大基金持股 | +4.19% | +0.13% | | | = AI PC ...

Core Viewpoint - The innovative drug sector experienced a significant drop in both Hong Kong and A-share markets, with declines exceeding 6% in various segments, including oncology and CXO [1][3]. However, research institutions view this downturn as a buying opportunity, suggesting that the upward trend in the pharmaceutical sector is likely to continue in the medium to long term [1][6]. Market Performance - Early trading saw a collective decline in the innovative drug sector, with notable stocks like BeiGene and Eucure Biopharma dropping over 10% [1]. The decline was later mitigated, with Eucure Biopharma turning positive and BeiGene's drop narrowing to under 5% [2]. External Factors - A sudden market downturn was attributed to concerns over potential U.S. government restrictions on drug imports from China, which could disrupt experimental therapies and impact the U.S. pharmaceutical industry [4]. However, the White House indicated that there was no active consideration of such a proposal [5]. Analyst Insights - Despite the negative news, analysts from Dongwu Securities and Guotai Junan believe that the downturn presents a buying opportunity, emphasizing the competitive advantage of Chinese innovative drug companies in the U.S. biotech landscape [6][7]. They argue that the profitability of multinational corporations (MNCs) from Chinese drug pipelines remains significant, with MNCs benefiting more from the profits generated [6]. Long-term Outlook - Analysts from Citic Securities maintain that the pharmaceutical sector's upward momentum is far from over, recommending a focus on innovation-driven and internationalization strategies, particularly in sectors with strong domestic demand [7]. The potential impact of any administrative orders is considered limited, given the historical challenges faced by similar policies in the U.S. judicial system [7].

近日，药明康德在2025年EcoVadis企业社会责任评级中再次获得"金牌"认证。这一认可充分体现了药明 康德对可持续发展的坚定承诺，以及将环境及社会责任融入战略规划和业务运营的不懈努力。 EcoVadis于2007年在法国巴黎成立，其前身是由TFS-CI("携手实现可持续发展"-全球化学联盟)、UN Global Compact(联合国全球契约组织)、IPE公众环境研究中心等NGO(非政府组织)构建的一个专门应用 于其下游各国际供应链管理组织而搭建的系统平台。 EcoVadis"金牌"仅授予所在所有参评企业的前5%。药明康德能够连续两年在EcoVadis企业社会责任评级 中获得"金牌"认证，可见其在行业内的优异表现。 事实上，一直以来药明康德就在各类可持续发展评级中获得全球权威机构的高度认可。截至目前，药明 康德已连续五年获得MSCI ESG领导力评级；连续四年入选道琼斯可持续发展指数(DJSI)；连续三年获 得CDP气候变化"A-"级领导力评级、Morningstar Sustainalytics ESG"行业最高评级"及"区域最高评级"、 入选富时罗素社会责任指数系列；首次获得MSCI ESG "AAA ...